جست‌وجوی استاد و پژوهشگر

Junco Warrenمشاهده پروفایل

استادیار

• Energy Metabolism
• Mitochondrial Bioenergetics
• Heart Failure Therapy
• +۳ مورد دیگر

Junco Warren, PhD, is an Assistant Professor at the Fralin Biomedical Research Institute and Virginia Tech’s Department of Human Nutrition, Foods, and Exercise. She holds an adjunct appointment at Kumamoto University, Japan. Her research focuses on metabolic reprogramming in heart failure, particularly mechanisms linking energy metabolism dysfunction to cardiac pathology. Key interests include mitochondrial bioenergetics, metabolomics, and epigenetic regulation in cardiac disease. Education: PhD in Pharmacology (SUNY Medical School, 2007), B.A. in International Economics (Aoyama-Gakuin University, 1997). Research Interests: Her work investigates how metabolic dysregulation drives heart failure progression, with emphasis on PERM1 and Smyd1 proteins. Projects include metabolomics-based biomarker discovery and therapeutic strategies targeting mitochondrial function. Awards: Notable recognitions include the 2023 Seale Innovation Award, 2016 BCVS Early Career Investigator Award, and multiple NIH and American Heart Association grants. Grants/Advising: Leads the Warren Lab, mentoring graduate and undergraduate students. Current projects involve PERM1 gene therapy in heart failure models and collaborations on mitochondrial dysfunction mechanisms. Lab Affiliations: Center for Vascular and Heart Research at Fralin, with international collaborations in Japan and the U.S.

H. Courtney Hodgesمشاهده پروفایل

دانشیار

• Epigenomics
• Disordered protein
• Chromatin and epigenetics
• +۵ مورد دیگر

H. Courtney Hodges is an Associate Professor at Baylor College of Medicine , with adjunct faculty status in the Department of Bioengineering at Rice University . She leads a lab focused on chromatin biology , transcription regulation , and cancer epigenetics , particularly the role of ATP-dependent chromatin remodelers like SWI/SNF (BAF) and disordered proteins in disease mechanisms. Department of Molecular and Cellular Biology , Baylor College of Medicine Center for Precision Environmental Health , Baylor College of Medicine Dan L Duncan Comprehensive Cancer Center , Baylor College of Medicine Graduate Programs in Genetics/Genomics and Cancer/Cell Biology Adjunct Faculty , Rice University Department of Bioengineering Education: Ph.D. from U.C. Berkeley, Postdoctoral Fellowship at Stanford University School of Medicine. Her research interests include epigenomics, disordered protein interactions, chromatin dynamics, and translational applications in cancer therapy. She develops interdisciplinary methods combining epigenomic analysis , live-cell imaging , and chemical biology to study these systems. Recent publications highlight her work on SWI/SNF-chromatin interactions, disordered protein modules in transcription, and the therapeutic potential of epigenetic and chromatin-targeting drugs. Her lab contributes to understanding signal integration in gene expression , with implications for AML , bladder cancer , and developmental disorders . Scientific Awards: V Scholar Award Medical Research Award from Gabrielle's Angel Foundation for Cancer Research CPRIT Faculty Scholar Advising: Mentors graduate students and postdoctoral fellows , including Eric Smith , Courtney Chambers , and Sanjay Nagaraj . Her lab is affiliated with the Texas Medical Center , enabling collaboration with clinicians and researchers across institutions. She advocates for interdisciplinary training in wet-lab and computational epigenomics.

• Muscle Physiology
• Malignant Hyperthermia
• Ryanodine Receptor Structure-Function
• +۳ مورد دیگر

Professor P D Allen is a Professor of Anaesthesia at the University of Leeds, UK, and holds Emeritus status at Harvard Medical School. His research focuses on muscle physiology, malignant hyperthermia, and calcium regulation in striated muscles. He has held academic and clinical roles across institutions including Harvard, Brigham and Women’s Hospital, and UC Davis. Notable awards include the MHAUS Distinguished Contribution Award (2007) and FAER Honorary Lecturer (2006). His work explores ryanodine receptor structure-function relationships and gene therapy applications using CRISPR-Cas9. Education: PhD in Physiology, University of Florida (1973) MD, Boston University (1967) BA in Medicine, Boston University (1967) Research Interests: Over 40 years, Prof. Allen’s work has centered on calcium regulation in muscle cells, particularly the ryanodine receptor’s role in E-C coupling. He pioneered genetically engineered mouse models (e.g., dyspedic mice) to study protein interactions and has explored HSV1/AAV vectors for gene therapy in diseases like Duchenne muscular dystrophy. Recent advancements include CRISPR-Cas9 for creating disease models. Awards: Academy of Anesthesia Mentors Founding Member (2004) Vandam Lecturer (2001) Paul D. Allen Chair in Anesthesia Research (2007) Professional Memberships: American Society of Anesthesiology Biophysical Society Academy of Anesthesia Mentors (FAER) Labs/Teams: Active in the Leeds Institute of Medical Research at St James’s, collaborating on E-C coupling protein interactions and gene therapy vectors.

Anne Skaja Robinsonمشاهده پروفایل

استاد

• Biotechnology
• Pharmaceutical Engineering
• Neurodegeneration
• +۵ مورد دیگر

Dr. Anne Skaja Robinson is a Trustee Professor of Chemical Engineering and Biomedical Engineering at Carnegie Mellon University (CMU), serving as Department Head from 2018–2023. Previously, she held leadership roles at Tulane University and the University of Delaware. Her research focuses on protein folding/aggregation, neurodegeneration (tau pathology), and biopharmaceutical production. She has over 85 publications, 23 Ph.D. graduates, and honors including the NSF PECASE Award and AIChE fellowship. Education: B.S., M.S. (Johns Hopkins University, 1988–1989); Ph.D. (University of Illinois at Urbana-Champaign, 1994). Professional roles include Board Member of AIChE (2015–2017), FDA Advisory Committee member, and editorial board positions for Biotechnology and Bioengineering and Biotechnology Journal . Research interests span: (1) GPCR expression and signaling, (2) protein aggregation control for antibodies and AAVs, (3) tau protein mechanisms in Alzheimer’s, and (4) machine learning for gene therapy vector optimization. Recent work applies computational tools to improve AAV production quality. Articles highlight advancements in GPCR dynamics, tau aggregation kinetics, and biomanufacturing process control. Awards recognize her contributions to biotechnology and engineering education. Her lab actively collaborates on FDA advisory work and NIH/NSF projects.

Aurélien Lathuilièreمشاهده پروفایل

پژوهشگر

• Neurodegenerative Disorders
• Alzheimer’s Disease
• Tau Pathology
• +۳ مورد دیگر

Aurélien Lathuilière is a faculty neurologist and researcher at the Memory Center of Geneva University Hospitals, affiliated with the University of Geneva. He holds a dual background in clinical neurology and neuroscience, with expertise in neurodegenerative disorders, particularly Alzheimer’s disease and tauopathies. His academic journey includes a MD-PhD from the University of Geneva and Harvard Medical School postdoctoral training, focusing on tau pathophysiology. His research focuses on tau protein mechanisms, including cell-to-cell propagation, diagnostic biomarkers, and therapeutic interventions using encapsulated cell technology. Collaborations with biotech companies and patents in cellular delivery systems highlight his translational research focus. Key contributions include studies on fecal microbiota transplantation’s effects in Alzheimer’s models, plasma biomarker validation (e.g., p-tau217), and tau seeding detection via biosensor cells. He also investigates LRP1 and SORL1 receptors’ roles in tau metabolism. Lab members include master student Hadrien Lalive d’Epinay. His work bridges clinical practice at the Memory Center with laboratory research, aiming to advance diagnostic tools and therapies for neurodegenerative diseases.

Allison May Keeler-Klunkمشاهده پروفایل

استادیار

• Gene Therapy
• Adeno-Associated Virus (AAV) Vectors
• Immunology of Gene Therapy
• +۶ مورد دیگر

Allison May Keeler-Klunk is an Assistant Professor in the Department of Genetic and Cellular Medicine at UMass Chan Medical School, with additional appointments in the NeuroNexus Institute and multiple graduate programs including Immunology and Microbiology, Neuroscience, and Translational Science at the Morningside Graduate School of Biomedical Sciences. She leads the Keeler Lab for Gene Therapy, focusing on understanding and engineering immune responses to enhance gene therapy efficacy. Dr. Keeler-Klunk earned her BS in Biotechnology from Rochester Institute of Technology and her PhD in Biomedical Sciences from University of Massachusetts Medical School. Her research spans three primary areas: CAR Treg Cell Therapies, Gene Editing of Hematopoietic Stem and Progenitor Cells (HSPCs), and Fatty Acid Oxidation Disorders, with a particular focus on Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) deficiency. Her laboratory investigates immune responses to adeno-associated virus (AAV) gene therapy vectors, developing chimeric antigen receptor (CAR) T-cells and CAR T-regulatory cells to model and mitigate immune responses that limit therapeutic efficacy. Recent work has focused on understanding why immune responses to AAV differ between clinical trials, developing models to predict these responses, and creating strategies to suppress destructive immune reactions while preserving therapeutic gene expression. Analysis of her recent publications reveals a strong focus on AAV vector immunogenicity, CNS-directed gene therapy, CAR Treg applications, and therapeutic strategies for genetic disorders including muscular dystrophies, lysosomal storage diseases, and fatty acid oxidation disorders. Her work bridges basic immunology with translational applications, addressing critical barriers in gene therapy clinical implementation. Dr. Keeler-Klunk serves as Principal Investigator of the Keeler Lab and contributes to the Immunology Core, providing high-quality immunoassays for AAV clinical trials. Her laboratory actively seeks partnerships for knowledge exchange, consulting, academic/industry collaborations, sponsored research, and spinout activities.

Philippe Gallayمشاهده پروفایل

استاد

• Virology
• Immunology
• Antiviral Therapeutics
• +۳ مورد دیگر

Philippe Gallay, PhD, is a Professor of Immunology in the Department of Immunology and Microbial Science at The Scripps Research Institute. His research focuses on the interplay between host factors and viruses, particularly HIV and HCV, aiming to develop novel antiviral therapies. He holds a PhD in Bacteriology/Immunology from the University of Lausanne (1993) and has held academic positions since 1997, including roles as Professor and Associate Professor. Key research interests include HIV latency reversal, HBV cure strategies using AAV vectors, and SARS-CoV-2 therapies targeting viral entry mechanisms. His lab has pioneered cyclophilin inhibitors (e.g., CRV431) for HCV and HIV, and developed nasal sprays to combat SARS-CoV-2 variants. Notable publications span antiviral drug combinations, viral replication mechanisms, and translational models in humanized mice. Awards: 1994 AIDS Award (Bristol-Myers Squibb), Prix Brunner Thesis Award (University of Lausanne). Grants/Labs: Collaborations on HBV cure strategies using AAV vectors, HIV latency reversal via IAP antagonists, and SARS-CoV-2 antivirals like astodrimer sodium. His work spans virology, pharmacology, and translational medicine, with a focus on high-impact human health threats like HIV, HCV, and emerging viruses.

Richard Jude Samulskiمشاهده پروفایل

استاد

• Gene Therapy
• Virology
• Molecular Biology
• +۳ مورد دیگر

Richard Jude Samulski, PhD , is a Professor of Pharmacology at the University of North Carolina School of Medicine and a founding member of the UNC Gene Therapy Center . As a gene therapy pioneer, he has dedicated over 30 years to advancing adeno-associated virus (AAV) as a safe, efficient viral vector for human gene therapy. His research focuses on AAV's molecular biology, including its site-specific integration into host DNA, with applications in treating genetic disorders like Duchenne muscular dystrophy. Alumni Distinguished Professor Director, UNC Vector Core Co-founder of Asklepios BioPharmaceutical (AskBio) Research Interests : Samulski's lab investigates the nonpathogenic AAV as a eukaryotic viral vector, developing packaging systems for foreign gene delivery, characterizing cis-acting sequences for DNA integration, and addressing immune response challenges in clinical applications. His work bridges basic virology and translational medicine. Scientific Contributions : Led breakthrough research in AAV vector design, enabling long-term gene expression and inspiring clinical trials for Duchenne muscular dystrophy. Collaborations with the Muscular Dystrophy Association and Pfizer brought experimental treatments to human trials. Lab Members : His team includes postdocs, graduate researchers, and technicians working on AAV replication, integration, and clinical optimization. Key members: Lauriel Freya Earley (Post-Doc), Wenwei Shao (Post-Doc), Melisa Vance (Post-Doc Trainee), and Kenton Woodard (Graduate Research Assistant).

Yajie (Kevin) Liangمشاهده پروفایل

استادیار

• Neural stem cell therapy
• Two-photon imaging
• Neurogenesis
• +۵ مورد دیگر

Yajie (Kevin) Liang, MB, PhD, is an Assistant Professor in the Department of Diagnostic Radiology and Nuclear Medicine at the University of Maryland School of Medicine. He is a Principal Investigator at the Center for Advanced Imaging Research (CAIR) and a member of the Marlene and Stewart Greenebaum Comprehensive Cancer Center. His interdisciplinary research bridges neuroscience, imaging technology, and regenerative medicine. Education and Training: 1998–2003: Baccalaureate in Medicine, 3rd Military Medical University, Chongqing, China 2003–2009: PhD in Neurobiology, 3rd Military Medical University, Chongqing, China 2010–2012: Postdoc, Department of Radiology, Johns Hopkins University 2012–2015: Postdoc, Institute of Physiology, Tübingen University, Germany Research Focus: Dr. Liang’s laboratory develops and applies advanced in vivo imaging techniques, particularly two-photon and three-photon microscopy, to study neural stem cell therapy, stroke recovery, and neurodegeneration. His team investigates how transplanted neural cells integrate into host brain circuits and how toxic protein aggregates, such as α-synuclein, propagate in dementia models. Current Projects: Long-term tracking of single neural stem cells in stroke models Nanobody-based chemogenetic probes for α-synuclein strain imaging Smart multiphoton imaging systems for real-time cellular interrogation 3D-printed microinjection needle arrays for precise brain delivery Grants & Funding: NIA: “Shedding Light on Functional Heterogeneity of Dementia-related Alpha-synuclein Strains” ($463,124, 2022–2025) Maryland Stem Cell Research Fund: “Smart Intravital Multiphoton Imaging iPSC-derived Cells” ($345,000, 2024–2026) NIMH subcontract: “3D Microprinting-Enabled Microinjection Needle Arrays” ($88,295, 2023–2025) Total active funding: $896,419 Scientific Awards: Young Investigator Award, National Natural Science Foundation of China (2009) Outstanding Doctoral Thesis, Chongqing City (2010) Fortune Award for Junior Investigators, Tübingen University (2013) Dr. Liang is an active member of the Society for Neuroscience, Society for Image Guided Neurointerventions, and BioImaging North America. His work has been featured in high-impact journals including Nature Methods , Cell Research , and Biomaterials .

Jason Steelمشاهده پروفایل

مدرس ارشد

• Molecular Gene Therapy
• Immunology
• Immunotherapy
• +۶ مورد دیگر

Dr. Jason Steel is a Senior Lecturer in Medical Laboratory Science and Biotechnology at CQUniversity's School of Health, Medical and Applied Sciences, where he has been employed since September 2018. His academic career includes previous positions at the University of Queensland, Translational Research Institute, University of Cincinnati College of Medicine, and the National Institutes of Health/National Cancer Institute in the USA. He co-founded Ocugene, a startup developing molecular therapies for ocular diseases. Dr. Steel's research focuses on: Molecular gene therapy platforms including AAV vectors for ocular diseases Cancer immunology and immunotherapy approaches Tumour microenvironment and metastasis mechanisms Development of cancer vaccines and targeted therapies Ocular disease modeling and treatment innovation His recent publications (2020-2024) demonstrate strong emphasis on: AAV-mediated gene therapies for retinal and choroidal diseases Molecular mechanisms in uveal melanoma pathogenesis MicroRNA regulation in cancer metastasis Novel therapeutic approaches for hepatocellular carcinoma Ocular drug delivery challenges and solutions Honors include: NIH Fellows Award for Research Excellence (FARE) - Awarded three times 2017 University of Queensland Faculty of Medicine: Leader of the Future (Academic) Dr. Steel maintains an active research supervision portfolio with accreditation in six fields: Biochemistry/Cell Biology, Medical Biotechnology, Immunology, Oncology, Ophthalmology, and Pharmacology. He coordinates multiple courses including Applied Immunology, Molecular Targeted Therapies, and Drug Discovery & Clinical Trials.

Oliver J. Müllerمشاهده پروفایل

استاد

• Translational Cardiology
• Cardiovascular Diseases
• Heart Failure
• +۵ مورد دیگر

Oliver J. Müller serves as DZHK Professor for Translational Cardiology at Kiel University and holds an attending physician position at the Department of Internal Medicine III, University Hospital Schleswig-Holstein. His research focuses on identifying novel therapeutic targets for cardiovascular diseases including heart failure, cardiomyopathies, peripheral artery disease, Marfan syndrome, and cardio-oncology. Prof. Müller's laboratory investigates metabolic, inflammatory, and epigenetic mechanisms driving cardiac remodeling under hemodynamic stress or oncological cardiotoxicity. His team develops optimized adeno-associated virus (AAV) vectors for cardiac and vascular gene transfer, bridging preclinical discoveries with clinical applications. As a clinician-scientist, he leads trials in stem cell therapy for vascular disease and anti-inflammatory approaches for heart failure, emphasizing translational impact from bench to bedside. His publication record demonstrates consistent innovation in cardiovascular gene therapy, with recurring themes in AAV vector engineering, molecular mechanisms of cardiac remodeling, and cardio-oncology applications across diverse models from mice to large animals. Major recognitions include: Research Award “Benny & Co” of the German Muscular Dystrophy Foundation (2017) Research Award German Marfan Foundation (2016) Poster Award of the European Society of Cardiology (2014) Research Award Benny & Co of the German Muscular Dystrophy Foundation (2013) Franz-Maximilian-Groedel-Research Award of the German Society of Cardiology (2009) Prof. Müller directs a DZHK-affiliated laboratory focused on advancing AAV-based therapies toward clinical translation for severe hereditary cardiovascular conditions, maintaining active collaborations within the German Center for Cardiovascular Research network.

Christopher H. Evansمشاهده پروفایل

استاد

• Gene Therapy
• Musculoskeletal Biology
• Osteoarthritis
• +۷ مورد دیگر

Christopher H. Evans, Ph.D., is a Professor at Mayo Clinic College of Medicine and Science, with primary appointments in the Department of Physical Medicine & Rehabilitation and joint appointments in the Department of Orthopedic Surgery and Department of Molecular Medicine at Mayo Clinic, Rochester, Minnesota. He holds the distinguished title of John and Posy Krehbiel Professor of Orthopedics and serves as Director of the Rehabilitation Medicine Research Center and Principal Investigator of the Musculoskeletal Gene Therapy Research Laboratory. John and Posy Krehbiel Professor of Orthopedics (2019) President, Orthopaedic Research Society (2004–2005) Marshall R. Urist, MD Award (2009) Arthur Steindler, MD Award (2010) Honorary Fellow, Swansea University (2009) Dr. Evans’ research leverages gene therapy to develop novel treatments for osteoarthritis and musculoskeletal tissue regeneration. His work spans from basic molecular biology to clinical translation, with a focus on intra-articular gene delivery, bone healing, and cartilage repair. He investigates how inflammatory mediators like IL-1β affect stem cell differentiation and tissue regeneration, aiming to modulate these pathways for therapeutic benefit. The recent publication trends highlight a strong focus on gene therapy for arthritis, particularly using IL-1Ra and BMP-2, as well as innovative approaches like chemically modified RNA and mechanical modulation for bone healing. His studies span preclinical models to human clinical trials, demonstrating a robust translational pipeline. Key themes include chondrocyte senescence, matrix stiffness, epigenetic regulation, and dual-gene delivery systems. Dr. Evans has secured significant research funding, including grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the Congressionally Directed Medical Research Programs. His laboratory actively mentors postdoctoral fellows and collaborates on multidisciplinary projects aimed at improving outcomes in orthopedics and rehabilitation medicine. His lab, the Musculoskeletal Gene Therapy Research Laboratory, is at the forefront of developing single-operation, gene-based therapies for osteoarthritis and non-healing fractures, with the goal of reducing disability and healthcare costs. The lab’s work integrates molecular biology, biomechanics, and clinical research to advance regenerative orthobiologics.

• Gene Therapy
• Molecular Physiology of Hearing
• Auditory Synapses
• +۷ مورد دیگر

Saaid Safieddine is a Permanent Researcher (DR2 CNRS) at the Institut Pasteur in Paris, where he co-leads the Auditory Cognition and Communication team. His research focuses on developing translational gene therapies for hereditary and acquired hearing loss, particularly targeting genetic deafness such as DFNB9 caused by otoferlin mutations. He works within a multidisciplinary team that includes engineers, researchers, and ENT surgeons, aiming to bridge molecular discoveries with clinical applications through robotic delivery systems. His primary research interests include: Molecular physiology of hearing and auditory synapses Gene therapy for inner ear abnormalities Adeno-associated virus (AAV) vector design and tropism Otoferlin gene expression and regulation Translational neuroscience and preclinical modeling Cell-specific targeting in the inner ear His recent publications (2019–2025) demonstrate a consistent and impactful research trajectory in gene therapy for deafness. The work shows a progression from foundational studies on synaptic mechanisms to advanced preclinical models and clinical translation. Key themes include the development of dual-AAV systems for otoferlin delivery, in vivo tropism studies across developmental stages, restoration of auditory processing, and expanding therapeutic time windows in Usher syndrome models. His research increasingly integrates developmental biology, viral engineering, and behavioral neuroscience to address the full spectrum of hearing restoration. Saaid Safieddine has not been noted to have received specific scientific awards in the provided texts. However, his leadership in high-impact projects such as the ANR "Robocop" initiative and collaborations with clinical centers (Pitié-Salpêtrière and Necker Hospitals) indicate significant research funding and institutional support. He supervises PhD students and postdoctoral researchers, contributing to the training of next-generation scientists in auditory neuroscience and gene therapy. He is involved in multidisciplinary research teams and collaborative projects that integrate: The Auditory Cognition and Communication team at Institut Pasteur The RobOtol robotic surgery project for otological interventions Clinical ENT departments at Pitié-Salpêtrière and Necker University Hospitals The Hearing Institute for translational development ANR-funded projects like "Robocop" for active cochlear implants

Terence R. Flotteمشاهده پروفایل

استاد

• Gene Therapy
• Adeno-Associated Virus Vectors
• Alpha-1 Antitrypsin Deficiency
• +۵ مورد دیگر

Terence R. Flotte, MD is a Professor at UMass Chan Medical School and the Principal Investigator of the Flotte Lab for Gene Therapy at the Horae Gene Therapy Center. His research focuses on developing gene therapy approaches for genetic diseases affecting children, with particular emphasis on alpha-1 antitrypsin deficiency, cystic fibrosis, and fatty acid oxidation disorders. Dr. Flotte's research interests include: Adeno-associated virus (AAV) vector development for gene therapy Gene therapy for alpha-1 antitrypsin deficiency Cystic fibrosis gene therapy Gene therapy for fatty acid oxidation disorders Central nervous system gene therapy Gene editing approaches using CRISPR/Cas9 Dr. Flotte's recent publications demonstrate a strong focus on translational gene therapy research, with multiple clinical trials underway for lysosomal storage disorders like GM2 gangliosidosis and GM1 gangliosidosis. His work spans from basic vector engineering to clinical applications, with particular attention to delivery methods, immune responses, and safety considerations. Recent publications highlight advances in base editing for alpha-1 antitrypsin deficiency, novel delivery methods including robot-assisted intrathalamic infusion, and detailed characterization of immune responses to AAV vectors. Dr. Flotte has contributed significantly to the field through numerous reviews and editorials that provide historical perspective on gene therapy development and discuss current challenges and future directions.

Edward Changمشاهده پروفایل

استاد

• Epilepsy
• Brain Tumors
• Neurosurgery
• +۳ مورد دیگر

Edward Chang serves as Chair of the Department of Neurological Surgery at the University of California, San Francisco (UCSF), where he is a Professor specializing in surgical therapies for epilepsy, brain tumors, and trigeminal neuralgia. His expertise centers on advanced neurophysiologic brain mapping to preserve speech and motor function during neurosurgical procedures, significantly impacting clinical outcomes for patients with complex neurological conditions. His educational foundation includes: BA in Amherst College (1997) MD from UCSF (2004) Neurosurgery Residency at UCSF (2004-2010) Fellowship in Cognitive Neurophysiology at UC Berkeley's Helen Wills Neuroscience Institute (2008-2009) Chang's research pioneers the intersection of neurosurgery and neural engineering, with primary focus on speech neuroprosthetics, brain tumor heterogeneity, and intracranial biomarker development. His team employs electrophysiological mapping, machine learning, and neurostimulation to decode neural activity for communication restoration in paralyzed patients and optimize surgical approaches for epilepsy and gliomas. This work bridges fundamental neuroscience with transformative clinical applications. Analysis of his 2025 publications reveals dominant themes in speech decoding neuroprosthetics (including multilingual systems and avatar control), glioma molecular evolution, and closed-loop deep brain stimulation for depression/OCD. These studies leverage high-density intracranial recordings to identify personalized neural biomarkers, demonstrating a clear trajectory toward individualized neuromodulation therapies and real-time brain-computer interfaces. His scientific recognition includes: Member of the National Academy of Medicine (2020) Blavatnik National Award Laureate in Life Sciences (2015) Bowes Biomedical Investigator (2018) NIH New Director's Innovation Award (2011-2016) New York Stem Cell Foundation Robertson Investigator (2015-2020) Klingenstein Fellowship Award (2011) Pathway to Independence Award (2009-2013) Alpha Omega Alpha (2003) UCSF Dean's Prize for Research (2004) Young Investigator Award from Grass Foundation-American Epilepsy Society (2011) Chang directs substantial NIH-funded research programs including the BRAIN Initiative opportunities, with grants spanning neural decoding (DP2), stem cell applications, and depression biomarker development. While specific advisees aren't listed in source materials, he mentors surgical residents and fellows within UCSF's neurological surgery program. His clinical team at UCSF specializes in comprehensive brain tumor care and epilepsy surgery, integrating cutting-edge research with patient treatment protocols. The Chang Lab operates at the forefront of translational neuroscience, maintaining active projects in speech neuroprosthetics (including the high-performance system published in Nature 2024), closed-loop DBS for psychiatric disorders, and molecular profiling of glioma progression. Current initiatives focus on scaling brain-computer interfaces for clinical deployment and developing personalized stimulation targets using stereoencephalography data.